This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MarketVIEW: Chlamydia Trachomatis Vaccines

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Chlamydia trachomatis vaccines

http://www.reportlinker.com/p0961709/MarketVIEW-Chlamydia-trachomatis-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Chlamydia trachomatis (CT) is an intracellular Gram-negative bacterium and a leading cause worldwide of sexually-transmitted disease and preventable blindness. The pathogen is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies.

Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are "silent" and unrecognized. This is of concern due to continued transmission especially among individuals below 30 years of age. Prophylatic vaccines could prevent CT primary infection, reinfection or lessen the incidence and severity of PID, or similar long-term sequelae. A key question for vaccine manufacturers is whether a CT vaccine would be deployed alongside HPV vaccines in the preadolescent population, thus providing a sizeable commercial opportunity. 

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for a putative CT vaccine until 2035. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on new adolescent vaccines. 

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL Contents – Summary presentation (MS PowerPoint based)Executive SummaryCommercial model – key outputsTotal available demand: Chlamydia vaccine, global, (000s doses)Total available demand: Chlamydia vaccine, high-income markets, (000s doses)Total available demand: Chlamydia vaccine, emerging markets, (000s doses)Total available market: Chlamydia vaccine, global, ($ 000s)Total available market: Chlamydia vaccine, by market, ($ 000s)Total available market: Chlamydia vaccine, price sensitivity analysis, ($ 000s)Chlamydia vaccine: country volume analysis, 2025 (000s doses)Chlamydia vaccine: country value analysis, 2025 ($ 000s)The role of a CT vaccineCommercial model – key assumptionsPricingModel forecast comparisons: June 2011 v currentChlamydia vaccine opportunity: target product profileOverall commercial model assumptions per countryChlamydia trachomatis: brief backgroundClinical featuresChlamydia trachomatis: natural history of infectionChlamydia trachomatis: global incidenceChlamydia trachomatis: global prevalenceUS epidemiologyUK epidemiologyReasons for increasing incidencePotential impact of a CT vaccineCompetitor landscape: overviewCompetitive environment: major playersChlamydia trachomatis vaccine – HPV, a relevant case study?HPV vaccines: analysis of country uptakeBibliographyDisclaimerAbout VacZine Analytics

PAGES: ~57 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs